133 related articles for article (PubMed ID: 26109001)
1. RETRACTED ARTICLE: The value of U-NGAL expression as a potential prognostic biomarker in patients with renal cancer after neoadjuvant chemotherapy with cisplatin.
Ebrahimi T; Pirasteh H; Rezakhaniha B; Dormanesh B; Rabati RG; Yahaghi E; Mokarizadeh A
Tumour Biol; 2015 Jun; ():. PubMed ID: 26109001
[No Abstract] [Full Text] [Related]
2. ARCHITECT® urine-neutrophil gelatinase-associated lipocalin (u-NGAL) assay as new prognostic marker for clear cell Renal Cell Carcinoma (ccRCC) (preliminary results).
Ben Khadhra H; Rose-Robert F; Herpe YE; Sevestre H; Choukroun G; Catherine L; Amant C; Saint F
Int Urol Nephrol; 2021 Jan; 53(1):59-67. PubMed ID: 32783115
[TBL] [Abstract][Full Text] [Related]
3. Investigations of renal function using the level of neutrophil gelatinase-associated lipocalin associated with single-dose of cisplatin during chemotherapy.
Maghsoudi O; Mirjalili SH; Dolatabadi M; Joshaghani MF; Zarea M; Yahaghi E; Mokarizadeh A
Diagn Pathol; 2015 Jul; 10():98. PubMed ID: 26170013
[TBL] [Abstract][Full Text] [Related]
4. Choline-phosphate cytidylyltransferase-α as a possible predictor of survival and response to cisplatin neoadjuvant chemotherapy in urothelial cancer of the bladder.
Hemdan T; Turker P; Malmström PU; Segersten U
Scand J Urol; 2018 Jun; 52(3):200-205. PubMed ID: 29475387
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
Shiga H; Heath EI; Rasmussen AA; Trock B; Johnston PG; Forastiere AA; Langmacher M; Baylor A; Lee M; Cullen KJ
Clin Cancer Res; 1999 Dec; 5(12):4097-104. PubMed ID: 10632346
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer.
Wenners AS; Mehta K; Loibl S; Park H; Mueller B; Arnold N; Hamann S; Weimer J; Ataseven B; Darb-Esfahani S; Schem C; Mundhenke C; Khandan F; Thomssen C; Jonat W; Holzhausen HJ; von Minckwitz G; Denkert C; Bauer M
PLoS One; 2012; 7(10):e45826. PubMed ID: 23056218
[TBL] [Abstract][Full Text] [Related]
7. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer.
Fujii T; Toyooka S; Ichimura K; Fujiwara Y; Hotta K; Soh J; Suehisa H; Kobayashi N; Aoe M; Yoshino T; Kiura K; Date H
Lung Cancer; 2008 Mar; 59(3):377-84. PubMed ID: 17905465
[TBL] [Abstract][Full Text] [Related]
8. Is Bcl-2 a predictive marker of neoadjuvant chemotherapy response in patients with urothelial bladder cancer undergoing radical cystectomy?
Turker P; Segersten U; Malmström PU; Hemdan T
Scand J Urol; 2019 Feb; 53(1):45-50. PubMed ID: 30806186
[No Abstract] [Full Text] [Related]
9. Evaluation of renal function using the level of neutrophil gelatinase-associated lipocalin is not predictive of nephrotoxicity associated with cisplatin-based chemotherapy.
Kos FT; Sendur MA; Aksoy S; Celik HT; Sezer S; Civelek B; Yaman S; Zengin N
Asian Pac J Cancer Prev; 2013; 14(2):1111-4. PubMed ID: 23621196
[TBL] [Abstract][Full Text] [Related]
10. Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study.
Gaspari F; Cravedi P; Mandalà M; Perico N; de Leon FR; Stucchi N; Ferrari S; Labianca R; Remuzzi G; Ruggenenti P
Nephron Clin Pract; 2010; 115(2):c154-60. PubMed ID: 20407275
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the cisplatin nephrotoxicity using the urinary neutrophil gelatinase-associated lipocalin (NGAL) in patients with head and neck cancer.
Peres LA; da Cunha AD; Assumpção RA; Schäfer A; da Silva AL; Gaspar AD; Scarpari DF; Alves JB; Girelli Neto R; de Oliveira TF
J Bras Nefrol; 2014; 36(3):280-8. PubMed ID: 25317609
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of urinary neutrophil gelatinase-associated lipocalin and urinary kidney injury molecule-1 as biomarkers of renal function in cancer patients treated with cisplatin.
Ghadrdan E; Ebrahimpour S; Sadighi S; Chaibakhsh S; Jahangard-Rafsanjani Z
J Oncol Pharm Pract; 2020 Oct; 26(7):1643-1649. PubMed ID: 32046578
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Chemotherapy with Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients with Muscle-invasive Bladder Cancer: A Retrospective Age-stratified Analysis on Safety and Efficacy.
Hemenway G; Lewis B; Ghatalia P; Anari F; Plimack ER; Kokate R; Handorf E; Deng M; Geynisman DM; Zibelman M
Eur Urol Oncol; 2023 Aug; 6(4):431-436. PubMed ID: 35792045
[TBL] [Abstract][Full Text] [Related]
14. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury.
Mishra J; Ma Q; Prada A; Mitsnefes M; Zahedi K; Yang J; Barasch J; Devarajan P
J Am Soc Nephrol; 2003 Oct; 14(10):2534-43. PubMed ID: 14514731
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Chemotherapy for Patients with Muscle-invasive Urothelial Bladder Cancer Candidates for Curative Surgery: A Prospective Clinical Trial Based on Cisplatin Feasibility.
Schinzari G; Monterisi S; Pierconti F; Nazzicone G; Marandino L; Orlandi A; Racioppi M; Cassano A; Bassi P; Barone C; Rossi E
Anticancer Res; 2017 Nov; 37(11):6453-6458. PubMed ID: 29061832
[TBL] [Abstract][Full Text] [Related]
16. Involvement of neutrophil gelatinase-associated lipocalin and osteopontin in renal tubular regeneration and interstitial fibrosis after cisplatin-induced renal failure.
Kashiwagi E; Tonomura Y; Kondo C; Masuno K; Fujisawa K; Tsuchiya N; Matsushima S; Torii M; Takasu N; Izawa T; Kuwamura M; Yamate J
Exp Toxicol Pathol; 2014 Sep; 66(7):301-11. PubMed ID: 24912749
[TBL] [Abstract][Full Text] [Related]
17. Is serum survivin expression a predictive biomarker in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy?
Bozkaya Y; Özdemir NY; Sezer S; Köstek O; Demirci NS; Yazıcı O; Erdem GU; Eren T; Zengin N
Cancer Biomark; 2018; 22(1):143-149. PubMed ID: 29562501
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil gelatinase-associated lipocalin as a marker of acute renal disease.
Haase M; Haase-Fielitz A; Bellomo R; Mertens PR
Curr Opin Hematol; 2011 Jan; 18(1):11-8. PubMed ID: 21102325
[TBL] [Abstract][Full Text] [Related]
19. Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin.
Maeda A; Ando H; Ura T; Muro K; Aoki M; Saito K; Kondo E; Takahashi S; Ito Y; Mizuno Y; Fujimura A
Anticancer Res; 2017 Sep; 37(9):5235-5239. PubMed ID: 28870959
[TBL] [Abstract][Full Text] [Related]
20. An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer.
Xylinas E; Hassler MR; Zhuang D; Krzywinski M; Erdem Z; Robinson BD; Elemento O; Clozel T; Shariat SF
Biomolecules; 2016 Sep; 6(3):. PubMed ID: 27598218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
